JP7523542B2 - 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 - Google Patents

免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 Download PDF

Info

Publication number
JP7523542B2
JP7523542B2 JP2022531001A JP2022531001A JP7523542B2 JP 7523542 B2 JP7523542 B2 JP 7523542B2 JP 2022531001 A JP2022531001 A JP 2022531001A JP 2022531001 A JP2022531001 A JP 2022531001A JP 7523542 B2 JP7523542 B2 JP 7523542B2
Authority
JP
Japan
Prior art keywords
group
alkyl
membered heterocycloalkyl
alkoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022531001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504249A (ja
JP2023504249A5 (enExample
Inventor
シュミーズ，ノーバート
ヴォルトマン，ラース
キルヒホフ，デニス
グェン，ティ・タン・ホェン
ワーベック，ニコラス
ベマー，ウルフ
ピーターセン，キルスティン
コバー，クリスティーナ
ストッキヒト，デトレフ
レヒナー，クリスティアン
マイアー，ロビン・ミヒャエル
ハーバート，シモン・アンソニー
ケルシュゲンス，イザベル・パトリツィア
コセムンド，ディルク
オフリンガ，リエンク
グリーズ，マレイケ
バーダー，ベンジャミン
Original Assignee
バイエル・アクチエンゲゼルシヤフト
バイエル ファーマ アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル・アクチエンゲゼルシヤフト, バイエル ファーマ アクチエンゲゼルシャフト filed Critical バイエル・アクチエンゲゼルシヤフト
Publication of JP2023504249A publication Critical patent/JP2023504249A/ja
Priority to JP2024069557A priority Critical patent/JP7802850B2/ja
Publication of JP2023504249A5 publication Critical patent/JP2023504249A5/ja
Application granted granted Critical
Publication of JP7523542B2 publication Critical patent/JP7523542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022531001A 2019-11-28 2020-11-24 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類 Active JP7523542B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024069557A JP7802850B2 (ja) 2019-11-28 2024-04-23 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19212252.1 2019-11-28
EP19212252 2019-11-28
EP20181065 2020-06-19
EP20181065.2 2020-06-19
PCT/EP2020/083198 WO2021105117A1 (en) 2019-11-28 2020-11-24 Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024069557A Division JP7802850B2 (ja) 2019-11-28 2024-04-23 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類

Publications (3)

Publication Number Publication Date
JP2023504249A JP2023504249A (ja) 2023-02-02
JP2023504249A5 JP2023504249A5 (enExample) 2024-05-13
JP7523542B2 true JP7523542B2 (ja) 2024-07-26

Family

ID=73476184

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022531001A Active JP7523542B2 (ja) 2019-11-28 2020-11-24 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類
JP2024069557A Active JP7802850B2 (ja) 2019-11-28 2024-04-23 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024069557A Active JP7802850B2 (ja) 2019-11-28 2024-04-23 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類

Country Status (22)

Country Link
US (2) US12478621B2 (enExample)
EP (1) EP4065574A1 (enExample)
JP (2) JP7523542B2 (enExample)
KR (1) KR20220122637A (enExample)
CN (4) CN119523983A (enExample)
AU (1) AU2020393384A1 (enExample)
BR (1) BR112022010112A2 (enExample)
CA (1) CA3163105A1 (enExample)
CL (1) CL2022001406A1 (enExample)
CO (1) CO2022007005A2 (enExample)
CR (1) CR20220236A (enExample)
DO (1) DOP2022000110A (enExample)
EC (1) ECSP22041839A (enExample)
GE (2) GEP20247646B (enExample)
IL (1) IL293213A (enExample)
JO (1) JOP20220131A1 (enExample)
MX (1) MX2022006466A (enExample)
PE (1) PE20231098A1 (enExample)
PH (1) PH12022551260A1 (enExample)
SA (1) SA522432734B1 (enExample)
TW (1) TWI894183B (enExample)
WO (1) WO2021105117A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024099684A (ja) * 2019-11-28 2024-07-25 バイエル・アクチエンゲゼルシヤフト 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CN117355531A (zh) * 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) * 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) * 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CA3228862A1 (en) * 2021-08-03 2023-02-09 Beigene, Ltd. Pyrazolopyridinone compounds
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
CN117088874A (zh) * 2022-05-19 2023-11-21 轩竹生物科技股份有限公司 二酰甘油激酶抑制剂及其用途
CN119998295A (zh) 2022-06-08 2025-05-13 因赛特公司 作为dgk抑制剂的三环三唑并化合物
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
JP2025163312A (ja) * 2022-09-06 2025-10-29 小野薬品工業株式会社 ジアシルグリセロールキナーゼαおよび／またはζ阻害活性を有する化合物およびその医薬用途
CN116283803A (zh) * 2022-12-05 2023-06-23 上海旭东海普药业有限公司 一种氟马西尼中间体的制备方法
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2025030002A2 (en) * 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
CN122094689A (zh) * 2023-09-04 2026-05-26 英矽智能科技知识产权有限公司 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗
CN119143671B (zh) * 2024-11-21 2025-05-16 九洲药业(杭州)有限公司 一种插羰反应一锅法简便合成喹啉酮衍生物的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517977A (ja) 2003-02-14 2006-08-03 アバニール・ファーマシューティカルズ マクロファージ遊走阻害因子の阻害剤およびそれらを同定するための方法
JP2015529224A (ja) 2012-09-06 2015-10-05 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2017019723A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone pde9 inhibitors
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105116A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435479A1 (de) 1994-10-04 1996-04-11 Bayer Ag Chinolon- und Naphthyridoncarbonsäure-Derivate
CZ303899B6 (cs) * 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
JP2005170792A (ja) 2002-11-22 2005-06-30 Mitsubishi Pharma Corp Ｌ−プロリン誘導体およびその医薬としての用途。
DE10337191A1 (de) 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
US20050239790A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
CA2587489C (en) 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
GB0605689D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
ES2620634T3 (es) 2008-10-09 2017-06-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activadores de piruvato quinasa humana
FR2953834B1 (fr) 2009-12-10 2012-01-13 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
PE20141371A1 (es) * 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US10357484B2 (en) 2015-07-17 2019-07-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017101763A1 (en) 2015-12-13 2017-06-22 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
US10604505B2 (en) 2016-03-15 2020-03-31 Natco Pharma Limited Modified process for the preparation of Ceritinib and amorphous form of Ceritinib
CN109575016B (zh) 2017-09-28 2022-01-04 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
JP2021506862A (ja) 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｔｌｒ７／８アンタゴニストおよびそれらの使用
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
SG11202100818RA (en) 2018-07-31 2021-02-25 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2020143626A1 (zh) 2019-01-08 2020-07-16 南京药捷安康生物科技有限公司 Pde9抑制剂及其用途
CN111471059B (zh) 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
CN111484477B (zh) 2019-01-29 2022-07-08 博瑞生物医药（苏州）股份有限公司 一种苯并吡啶酮杂环化合物及其用途
TWI816026B (zh) 2019-03-08 2023-09-21 大陸商藥捷安康(南京)科技股份有限公司 磷酸二酯酶抑制劑的用途和藥盒
US20220340597A1 (en) 2019-04-09 2022-10-27 Hoffmann-La Roche Inc. Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517977A (ja) 2003-02-14 2006-08-03 アバニール・ファーマシューティカルズ マクロファージ遊走阻害因子の阻害剤およびそれらを同定するための方法
JP2015529224A (ja) 2012-09-06 2015-10-05 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2017019723A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Aza-cyanoquinolinone pde9 inhibitors
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105116A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochemical Pharmacology，2000年，59(7)，763-772
Journal of Lipid Research，2016年，57(3) ，368-379

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024099684A (ja) * 2019-11-28 2024-07-25 バイエル・アクチエンゲゼルシヤフト 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類
JP7802850B2 (ja) 2019-11-28 2026-01-20 バイエル・アクチエンゲゼルシヤフト 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類

Also Published As

Publication number Publication date
SA522432734B1 (ar) 2025-05-22
EP4065574A1 (en) 2022-10-05
JP2023504249A (ja) 2023-02-02
IL293213A (en) 2022-07-01
PE20231098A1 (es) 2023-07-18
TW202134230A (zh) 2021-09-16
DOP2022000110A (es) 2022-06-30
CN119523983A (zh) 2025-02-28
US11998539B2 (en) 2024-06-04
ECSP22041839A (es) 2022-06-30
TWI894183B (zh) 2025-08-21
JOP20220131A1 (ar) 2023-01-30
AU2020393384A1 (en) 2022-06-09
CR20220236A (es) 2022-10-03
JP2024099684A (ja) 2024-07-25
WO2021105117A1 (en) 2021-06-03
US20230148194A1 (en) 2023-05-11
US12478621B2 (en) 2025-11-25
GEAP202415986A (en) 2024-02-12
MX2022006466A (es) 2022-08-17
BR112022010112A2 (pt) 2022-09-06
KR20220122637A (ko) 2022-09-02
PH12022551260A1 (en) 2024-06-03
CN115003665A (zh) 2022-09-02
US20230201186A1 (en) 2023-06-29
CN119424429A (zh) 2025-02-14
CN119564686A (zh) 2025-03-07
CL2022001406A1 (es) 2023-03-10
CN115003665B (zh) 2024-11-08
CA3163105A1 (en) 2021-06-03
JP7802850B2 (ja) 2026-01-20
GEP20247646B (en) 2024-07-25
CO2022007005A2 (es) 2022-06-10

Similar Documents

Publication Publication Date Title
JP7802850B2 (ja) 免疫活性化のためのｄｇｋアルファ阻害剤としての置換アミノキノロン類
CN115210238B (zh) 作为用于免疫激活的DGKα抑制剂的取代的氨基喹诺酮类
US20230062100A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
KR102317169B1 (ko) 2-(모르폴린-4-일)-1,7-나프티리딘
AU2015299173A1 (en) 2-(morpholin-4-yl)-l,7-naphthyridines
EP4074317A1 (en) Phosphorus derivatives as novel sos1 inhibitors
WO2017102091A1 (en) Heteroarylbenzimidazole compounds
EP4073072A1 (en) Pyrazolotriazines
EP4288437A1 (en) Map4k1 inhibitors
EP4188930A1 (en) Substituted heterocyclic compounds and therapeutic uses thereof
EA048866B1 (ru) ЗАМЕЩЕННЫЕ АМИНОХИНОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ DGKα ДЛЯ ИММУННОЙ АКТИВАЦИИ
EA050445B1 (ru) Замещенные аминохинолоны в качестве ингибиторов dgkalpha для иммунной активации
HK40072887B (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
HK40072887A (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240716

R150 Certificate of patent or registration of utility model

Ref document number: 7523542

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150